Iridex Corporation, a leader in laser-based medical systems for treating glaucoma and retinal diseases, reported its financial results for the first quarter of 2025, ending March 29. Total revenue for the quarter was $11.9 million, slightly up from $11.8 million in the first quarter of 2024. The Cyclo G6® product family revenue increased by 8% year-over-year to $3.2 million, driven by higher probe sales, with 13,900 Cyclo G6 probes sold compared to 13,300 in the previous year quarter. Additionally, 24 Cyclo G6 Glaucoma Laser Systems were sold, up from 22 systems in the same quarter of the prior year. In contrast, retina product revenue experienced a 3% decrease to $6.6 million, primarily due to lower Pascal system sales, partially offset by increased sales in medical and surgical systems. Iridex significantly reduced operating expenses by 32% compared to the previous year period. The company reported an increase in adjusted EBITDA to $0.4 million, showing an improvement of $2.9 million from an adjusted EBITDA loss of $2.5 million in the first quarter of 2024. Moreover, Iridex strengthened its balance sheet with a strategic investment, resulting in $10 million of proceeds, and reported cash and cash equivalents of $7.2 million as of March 29, 2025. The company is focused on continuing its operational improvements and is exploring additional partnerships and distribution agreements to leverage its global customer base.